Related references
Note: Only part of the references are listed.Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])
Alan B. Miller et al.
AMERICAN JOURNAL OF CARDIOLOGY (2021)
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association
Michelle M. Kittleson et al.
CIRCULATION (2020)
Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis
Richard K. Cheng et al.
JACC: CARDIOONCOLOGY (2020)
Transthyretin Amyloid Cardiomyopathy JACC State-of-the-Art Review
Frederick L. Ruberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
John G. F. Cleland et al.
EUROPEAN HEART JOURNAL (2018)
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
Lars H. Lund et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance
Alain Cohen-Solal et al.
ESC HEART FAILURE (2017)
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
Scott D. Solomon et al.
EUROPEAN HEART JOURNAL (2016)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction
Selma F. Mohammed et al.
JACC-HEART FAILURE (2014)
Transthyretin (TTR) Cardiac Amyloidosis
Frederick L. Ruberg et al.
CIRCULATION (2012)
Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction Results From the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) Trial
Mona Fiuzat et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin Transthyretin Cardiac Amyloid Study (TRACS)
Taslima Bhuiyan et al.
CIRCULATION-HEART FAILURE (2011)
The perindopril in elderly people with chronic heart failure (PEP-CHF) study
John G. F. Cleland et al.
EUROPEAN HEART JOURNAL (2006)
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:: the CHARM-Preserved Trial
S Yusuf et al.
LANCET (2003)
Share Paper
